Morgan Stanley lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 6.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 22,920,470 shares of the company’s stock after purchasing an additional 1,352,484 shares during the period. Johnson & Johnson accounts for about 0.8% of Morgan Stanley’s investment portfolio, making the stock its 10th biggest holding. Morgan Stanley owned approximately 0.85% of Johnson & Johnson worth $3,166,921,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the stock. PDS Planning Inc lifted its position in Johnson & Johnson by 10.8% during the 3rd quarter. PDS Planning Inc now owns 3,673 shares of the company’s stock worth $507,000 after acquiring an additional 357 shares during the last quarter. Trust Department MB Financial Bank N A raised its position in shares of Johnson & Johnson by 0.4% during the third quarter. Trust Department MB Financial Bank N A now owns 98,938 shares of the company’s stock valued at $13,670,000 after buying an additional 363 shares during the last quarter. Global Retirement Partners LLC raised its position in shares of Johnson & Johnson by 3.0% during the third quarter. Global Retirement Partners LLC now owns 12,394 shares of the company’s stock valued at $1,712,000 after buying an additional 365 shares during the last quarter. Canal Capital Management LLC raised its position in shares of Johnson & Johnson by 2.3% during the third quarter. Canal Capital Management LLC now owns 16,077 shares of the company’s stock valued at $2,221,000 after buying an additional 365 shares during the last quarter. Finally, Cribstone Capital Management LLC raised its position in shares of Johnson & Johnson by 1.2% during the third quarter. Cribstone Capital Management LLC now owns 32,102 shares of the company’s stock valued at $4,435,000 after buying an additional 376 shares during the last quarter. 66.56% of the stock is owned by institutional investors and hedge funds.

A number of research analysts have recently commented on JNJ shares. ValuEngine raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Thursday, December 13th. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $164.00 price objective for the company in a research report on Wednesday, December 12th. Morgan Stanley cut their price objective on shares of Johnson & Johnson from $153.00 to $130.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 2nd. Barclays reaffirmed an “equal weight” rating and set a $135.00 price objective (down previously from $137.00) on shares of Johnson & Johnson in a research report on Wednesday, January 23rd. Finally, Citigroup cut their price objective on shares of Johnson & Johnson from $148.00 to $139.00 and set a “neutral” rating for the company in a research report on Wednesday, January 2nd. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $142.81.

Shares of JNJ opened at $137.60 on Friday. The stock has a market cap of $369.17 billion, a PE ratio of 16.82, a P/E/G ratio of 2.13 and a beta of 0.68. Johnson & Johnson has a 52 week low of $118.62 and a 52 week high of $148.99. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.47 and a quick ratio of 1.20.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, January 22nd. The company reported $1.97 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.95 by $0.02. The business had revenue of $20.39 billion for the quarter, compared to analysts’ expectations of $20.27 billion. Johnson & Johnson had a net margin of 18.75% and a return on equity of 35.63%. The firm’s revenue for the quarter was up 1.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.74 earnings per share. Equities analysts predict that Johnson & Johnson will post 8.57 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 12th. Investors of record on Tuesday, February 26th were paid a $0.90 dividend. The ex-dividend date of this dividend was Monday, February 25th. This represents a $3.60 dividend on an annualized basis and a yield of 2.62%. Johnson & Johnson’s payout ratio is currently 44.01%.

Johnson & Johnson announced that its board has authorized a share buyback plan on Monday, December 17th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 1.5% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.

COPYRIGHT VIOLATION WARNING: This news story was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.watchlistnews.com/johnson-johnson-jnj-shares-bought-by-morgan-stanley/2896913.html.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: What causes a recession?

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.